Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 100%Moderate 0 · 0%High 0 · 0%

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Tivozanib may leads to lower serious adverse events (Grade 3 or 4) compared with sorafenib (targeted agent versus targeted agent) (low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
RR 0.85 [0.74, 0.97]
1 study · 516 participants
Low